Reproductive Issues in Adults with Congenital Heart Disease: Arrhythmias During Pregnancy: Importance, Diagnosis and Therapy

Even in healthy women, increased ectopic activity is commonly seen during pregnancy. Congenital heart defects - whether nonoperated or operated - are, in general, associated with an increased risk of arrhythmias to a greater or lesser extent. During pregnancy, congenital heart disease patients are at increased risk of presenting first time with a symptomatic arrhythmia or, if previously diagnosed, the risk of recurrence of their arrhythmia is increased. Antiarrhythmic therapy should in general be restricted to the presence of intolerable symptoms, hemodynamic compromise or threat to the fetus and to patients in whom the arrhythmia may be life-threatening. The risk/benefit ratio must be considered for both the mother and the fetus. Considerations include the stage of pregnancy as well as possible effects of therapy on labor, delivery, and lactation. Nearly all of the presently available antiarrhythmic drugs are classified as Category C drugs in pregnancy. Thus, we rely on observational reports. Safety data are discussed for various drugs, and recommendations for the treatment of various arrhythmias are presented in this review.

Key words:

Arrhythmias - Pregnancy - Congenital heart disease

References

• 1 Burkart Th A, Conti J B. Arrhythmias in the Pregnant Patient: Evaluation and Management. ACC Current Journal Review May/June/1999: 41-44
• 2 Chow Th, Galvin J, McGovern B. Antiarrhythmic Drug Therapy in Pregnancy and Lactation.  Am J Cardiol. 1998;  82 581-621
• 3 Joglar J A, Page R L. Treatment of Cardiac Arrhythmias During Pregnancy - Safety Considerations.  Drug Safety. 1999;  20 ((1)) 85-94
• 4 Cox J L, Gardner M J. Treatment of cardiac arrhythmias during pregnancy.  Prog Cardiovasc Dis. 1993;  36 137-178
• 5 Rotmensch H H, Elkayam U, Frishman W. Antiarrhythmic drug therapy during pregnancy.  Ann Intern Med. 1983;  98 487-497
• 6 Page R L. Treatment of arrhythmias during pregnancy.  Am Heart J. 1995;  130 871-876
• 7 Wagner X, Jouglard J, Moulin M. et al . Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human milk.   Am Heart J. 1990;  119 700-702
• 8 Frishman W H, Chesner M. Beta-adrenergic blockers in pregnancy.  Am Heart J. 1988;  115 147-152
• 9 Lip G Y H, Beevers M, Churchill D. et al . Effect of atenolol on birth weight.  Am J Cardiol. 1997;  79 1436-1438
• 10 Widerhorn J, Bhandari A K, Bughi S. et al . Fetal and neonatal adverse effects profile of amiodarone treatment during pregnancy.  Am Heart J. 1991;  22 1162-1165
• 11 De Wolf D, De Schepper J, Verhaaren H. et al . Congenital hypothyroid goiter and amiodarone.  Acta Paediatr Scand. 1988;  77 616-618
• 12 Ovadia M, Mitermayer B, Gifford L. et al . Human experience with amiodarone in the embrionic period.  Am J Cardiol. 1994;  73 316-317
• 13 McKenna W J, Harris L, Rowland E. et al . Amiodarone therapy during pregnancy.  Am J Cardiol. 1993;  51 1231-1233
• 14 Elkayam U, Goodwin T M. Adenosine therapy for supraventricular tachycardia during pregnancy.  Am J Cardiol. 1995;  75 521-523
• 15 Mitani G M, Harrison E C, Steingberg I. et al . Digitalis glycosides in pregnancy. In: Elkayam U, Gleicher N, editors. Cardiac problems in pregnancy: diagnosis and management of maternal and fetal disease. New York: Liss.; 1990: 417-427
• 16 Berlin C M. Pharmacologic considerations of drug use in the lactating mother.  Obstet Cynecol. 1981;  58 Suppl 1 17 a-23 s
• 17 Rosemond R L. Cardioversion during pregnancy.  JAMA. 1993;  269 3167
• 18 Meyer J, Leckner J E, Schochet S S. Paroxysmal tachycardia in pregnancy.  Am Heart J. 1931;  94 1901-1904